INTRODUCTION
============

The gut microbiota fulfills an important role, helping to protect its host from disease.[@B1][@B2] The gut microbiota inhibits the proliferation and colonization of pathogens by occupying potential intestinal niches and competing for nutrients.[@B1][@B3] Additionally, the gut microbiota contributes to the differentiation and maturation of resident intestinal immune cells, including Th17 cells, regulatory T cells, innate lymphoid cells, and IgA-producing B cells.[@B4] The gut microbiota also acts as a metabolic organ that interacts with host cells and provides the functional support required for the maintenance of homeostasis. For example, short chain fatty acids (SCFAs), which are the end products of anaerobic bacterial fermentation of dietary fiber in the intestine, have been shown to enhance the epithelial cell barrier and anti-inflammatory immune cell function. Among these SCFAs, butyrate is important for the maintenance of various aspects of colonic homeostasis, such as intestinal motility, visceral blood flow, and suppression of pathogen expansion.[@B5][@B6] Furthermore, the gut microbiota plays an essential role in the metabolism of bile acids. It has been established that the primary bile acids, cholic and chenodeoxycholic acid, are converted to more than 20 different secondary bile acid metabolites including deoxycholic acid (DCA) and lithocholic acid (LCA), by the gut microbiota.[@B7] The accumulation of secondary bile acids, especially DCA, causes mucosal and DNA damage, leads to increased reactive oxygen species, and promotes tumor growth. In contrast, some secondary bile acids inhibit the growth of pathogens, suggesting that bile acid metabolism and its regulation by the gut microbiota can have both beneficial and harmful effects in the intestine.[@B7]

Under normal physiological conditions, the microbiota receives nutritional niches from the host. In turn, the microbiota provides symbiotic support for the host in the form of intestinal homeostasis maintenance. Thus, the host and its commensal microbes have a mutualistic relationship. However, some resident bacteria can acquire virulence, shift from symbionts to pathobionts, and contribute to the development and progression of various gastrointestinal (GI) diseases. A growing number of studies suggest that disturbance of the intestinal microbiota and its metabolic functions are strongly correlated with the initiation and progression of GI diseases, including functional dyspepsia, severe diarrhea, IBD, colorectal cancer (CRC), celiac disease, and IBS.[@B8][@B9] It is now understood that disturbance of intestinal microbial communities, called dysbiosis, can be triggered by both extrinsic (e.g., diet, appendectomy, and antibiotic use) and intrinsic factors (e.g., genetics, stress, and aging). Here, we will review the pathogenic role of the gut microbiota in GI diseases.

PATHOBIONTS ARE INDUCED BY VARIOUS FACTORS AND CONTRIBUTE TO THE PATHOGENESIS OF GI DISEASES
============================================================================================

1. IBD
------

IBD, comprising UC and CD, is chronic, relapsing inflammation of the GI tract. The development of IBD is governed by complex interactions between environmental risk factors, gut microbiota, and host genetics.[@B10] Recently, the role of the gut microbiota in IBD pathogenesis has attracted considerable attention.[@B11][@B12] It has been well documented that the diversity and richness of the gut microbiota are significantly reduced in patients with IBD, a condition referred to as dysbiosis.[@B11][@B13] Moreover, the accumulation of certain pathobionts has been reported in both patients with IBD and animal models of IBD. This pathobiont accumulation may trigger, or at least contribute to, disease pathogenesis.[@B1][@B12] For example, there is increasing evidence that defects in the inflammasome or NOD like receptor family pyrin domain containing protein (NLRP) signaling can lead to intestinal dysbiosis accompanied by an accumulation of potential pathobionts.[@B14] *Nlrp6^-/-^* mice, which have impaired IL-18 production, are characterized by an abnormal expansion of the phyla *Prevotellaceae* and TM7. Prevotellaceae have the ability to enzymatically disrupt mucosal barrier function.[@B15] Members of the phylum *Prevotellaceae* also tend to be more abundant in intestinal biopsy samples isolated from patients with IBD.[@B16] Administration of dextran sodium sulfate (DSS), commonly used to trigger IBD-like experimental colitis in mice, induces significantly more severe inflammation in *Nlrp6^-/-^* mice than in wild-type mice.[@B17] Nlrp6 deficiency leads to upregulation of CCL5; thereby promoting intestinal inflammation due to the recruitment of innate and adaptive immune cells.[@B17] Notably, the colitogenic phenotypes observed in *Nlrp6^-/-^* mice are transmissible to wild-type mice upon co-housing with *Nlrp6^-/-^* mice.[@B17] This suggests that the *Nlrp6* deficiency in the host is not a requirement for the induction of colitogenic phenotypes; rather, dysbiosis driven by the *Nlrp6* deficiency is the key factor responsible for triggering IBD-prone phenotypes in *Nlrp6^-/-^* mice.[@B17] Likewise, mice deficient in *Nod2*, another gene known to be associated with CD susceptibility, also display alterations in their microbiota composition and increased susceptibility to DSS-induced colitis.[@B18] The colitogenic phenotype of *Nod2^-/-^* mice, like that of *Nlrp6^-/-^* mice, can be acquired by wild-type mice through co-housing.[@B18] However, unlike *Nlrp6^-/-^* mice, the bacterial strains that accumulate in *Nod2^-/-^* mice and drive this phenotype are unknown.

Mice deficient in IL-10 or IL-2 have also been used as a model of IBD-like spontaneous colitis. It is noteworthy that these animals either have no symptoms or develop only very mild colitis when housed under germ-free conditions, suggesting that the gut microbiota is a key driver of inflammation in these two models.[@B19][@B20] Interestingly, some bacterial strains are capable of causing intestinal inflammation in these mice.[@B21][@B22] For instance, monocolonization of germ-free *Il10^-/-^* or *Il2^-/-^* mice with a human commensal bacterium such as *Escherichia coli* or *Enterococcus faecalis*, results in intestinal inflammation, whereas monocolonization with another commensal bacterium *Bacteroides vulgatus*, does not. This type of intestinal inflammation is accompanied by increased production of two pro-inflammatory cytokines, IL-12 and IFN-γ Dual colonization of germ-free 129S6/SvEv *Il10^-/-^* mice by *E. coli* and *E. faecalis* induces more severe colitis than monocolonization does.[@B23] In contrast, neither monocolonization nor dual colonization by these bacterial strains can induce the development of colitis in germ-free wild-type mice.[@B21] Interestingly, colonization of germ-free HLA-B27 transgenic rats by *B. vulgatus*, but not *E. coli*, causes severe intestinal inflammation.[@B24] These findings indicate that complicated interactions between commensal bacteria and the host\'s genetic background determine the fate of genetically susceptible individuals, i.e., colitis or no colitis.

In addition to genetics, other factors such as the environment can also trigger the development of IBD through dysbiosis. For example, dietary fats induce dysbiosis, thereby leading to intestinal inflammation.[@B25] Devkota et al. demonstrated that taurocholic acid derived from dietary fats (milk-derived), but not from polyunsaturated fatty acids, promoted the expansion of a particular member of Deltaproteobacteria, a sulfate-reducing commensal bacterium *Bilophila wadsworthia* while reducing the abundance of Firmicutes. *B. wadsworthia* induced colitis in genetically susceptible IBD-prone *Il10^-/-^* mice,[@B26] but not in wild-type mice, and the resulting colitis was mediated by more pronounced antigenspecific Th1 immune responses.[@B27] *B. wadsworthia* produces hydrogen sulfate (H~2~S), a genotoxic chemical agent that is capable of causing inflammation. In this context, excessive protein ingestion raises the level of waste products in the colon, such as sulfates, nitrates, ammonium, and ethanolamine. These metabolites stimulate the overgrowth of sulfate-reducing bacteria such as *Desulfovibrio* spp. and *Desulfuromonas* spp.[@B28] Notably, these bacteria are much more prevalent in patients with IBD than in healthy subjects.[@B29] Given that the expansion of sulfate-reducing bacteria can also be induced by high dietary fats, it can be concluded that diet directly impacts mucosal immunity and IBD pathogenesis. Likewise, diets rich in fats and beef can induce the accumulation of potential pathobionts. The abundance of *Erysipelotrichaceae* and *Bacteroides fragilis* was significantly increased in subjects on diets rich in fat or beef.[@B30][@B31] Although the pathogenic roles of these bacteria remain largely unknown, they were identified as potential pathobionts by IgA coating.[@B32]

In a recent study, Palm et al. demonstrated that the binding of IgA to intestinal bacteria can discriminate colitogenic bacteria from harmless non-colitogenic bacteria within the gut microbiota.[@B32] IgA-binding intestinal bacteria induced more severe colitis when used to colonize germ-free mice after DSS administration.[@B32] Notably, IgA-binding bacteria were present in both mice and humans (patients with IBD). Thus, although IgA identifies potential IBD-related pathobionts, dietary factors may regulate the abundance of these pathobionts in the intestine. These findings support the notion that the typical western diet may promote alternations in the composition of the microbiota, resulting in an accumulation of colitogenic pathobionts, and perturbed colitogenic microbiota facilitates the development and/or progression of IBD. Smoking is a well-known environmental factor that exacerbates IBD symptoms.[@B33][@B34]

A meta-analysis showed that *Anaerostipes*, which convert lactate to butyrate, were lower in patients with IBD who smoked than in those that did not.[@B35] Thus, smoking may lead to decreased butyrate production by the microbiota. Given that butyrate contributes to intestinal homeostasis by enhancing epithelial barrier function and facilitating regulatory T cell development,[@B5][@B6] impaired butyrate production due to smoking may increase the susceptibility of the host to IBD.

Antibiotic treatment is one of the most potent factors that can lead to a disturbance in healthy intestinal microbiota. Studies have shown that administration of antibiotics in the first year of life is associated with the development of pediatric IBD.[@B36][@B37] Patients with IBD who were treated with ciprofloxacin and metronidazole had a reduced abundance of *Dorea*, *Butyricicoccus*, and *Coriobacteriaceae*.[@B36][@B37] Organic compounds produced by these bacteria, such as formate and butyrate, are important for the regulation of gut homeostasis. Additionally, gut dysbiosis driven by antibiotic use often results in the overgrowth of pathogens. For instance, the abundance of *Clostridium difficile* is effectively suppressed in a healthy intestine by other commensal microorganisms. However, once the healthy microbial community is disrupted by antibiotics, *C. difficile* can bloom in the gut and cause *C. difficile*-induced colitis.[@B38][@B39] *C. difficile* infection causes significant morbidity and mortality in hospitalized patients[@B40] and is a serious complication for patients with IBD. Although the precise mechanism is unclear, IBD is a risk factor for *C. difficile* infection.[@B41][@B42] Moreover, *C. difficile* infection also exacerbates IBD.[@B42][@B43]

A key mechanism by which gut dysbiosis increases susceptibility to *C. difficile* infection is perturbation of the luminal metabolic profile. It has been well documented that antibiotics significantly decrease the abundance of bacteria responsible for bile acid metabolism.[@B44] Given that these bacteria can convert primary bile acids into secondary bile acids, the ratio of primary to secondary bile acids is significantly increased after antibiotic treatment.[@B45] Primary bile acids are known to promote the growth of *C. difficile*, whereas secondary bile acids inhibit *C. difficile* growth.[@B45][@B46]

Buffie et al. recently identified *Clostridium scindens* as a key bacterium that suppresses the growth of *C. difficile*.[@B47] *C. scindens* has high levels of bile acid 7alpha-dehydroxylating activity, which converts primary bile acids to secondary bile acids. Interestingly, the abundance of *C. scindens* is significantly reduced in *C. difficile*-susceptible mice and humans.[@B47] Additionally, adoptive transfer of *C. scindens* into *C. difficile*-susceptible (antibiotic-treated) mice inhibited the germination of *C. difficile* spores *via* DCA production.[@B47] As it has been reported that the balance of primary and secondary bile acids in the intestine is perturbed in patients with IBD,[@B48][@B49] this dysbiosis-induced imbalance of microbial metabolites may be associated with the increased susceptibility to *C. difficile* of patients with IBD. Further studies focusing on the luminal metabolites produced by dysbiotic microbiota are needed to unravel the precise mechanisms involved in the increased susceptibility of patients with IBD to *C. difficile* colonization.

In addition to pathogen overgrowth, dysbiosis in IBD can also result in the loss of beneficial commensal bacteria, increasing the risk of intestinal inflammation. For instance, a lower abundance of *Faecalibacterium prausnitzii* is associated with a higher risk of postoperative recurrence of inflammation in patients with IBD, particularly CD patients.[@B50][@B51] *F. prausnitzii* is one of the most abundant anaerobic bacteria in the human gut. It has an important function, providing energy to colonocytes and maintaining overall intestinal health. There is also evidence that *F. prausnitzii* has strong anti-inflammatory effects. These effects are mediated by the induction of a tolerogenic cytokine profile, which includes lower IL-12 and IFN-γ production and elevated levels of IL-10.[@B51] Notably, in a mouse model of intestinal inflammation, oral administration of *F. prausnitzii* showed anti-inflammatory effects and ameliorated colitis.[@B51] These results indicate that *F. prausnitzii* can counterbalance dysbiosis and may be a promising candidate probiotic for the treatment of CD. What is still unclear is the cause of the reduced abundance of *F. prausnitzii* in patients with IBD. Further studies are needed to determine whether this approach can be translated into novel and effective IBD treatment options.

Taken together, these findings suggest that the incidence and prevalence of IBD are closely related to various parameters that can shift the status of individual members of the gut microbiota from symbiotic to pathobiotic ([Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

2. CRC
------

CRC is a common cancer, causing about 500,000 deaths worldwide every year. The incidence of CRC is higher in the western world,[@B52] and this increased incidence is largely due to the dietary differences between developed and developing countries. Recent meta-analyses indicate that diets rich in fiber are associated with a lower risk of CRC,[@B53] whereas consumption of saturated fat-rich foods such as red and processed meat, is strongly associated with an increased risk of CRC.[@B54][@B55] An epidemiological study showed that the incidence of CRC in African Americans who generally consume high-fat, low-fiber diets was higher than that of rural indigenous Africans who generally consume low-fat, high-fiber diets.[@B56] In addition, there were significant differences in the microbiota composition and the metabolic profiles of these two groups; fecal samples from African Americans had lower numbers of total bacteria and the major butyrate-producing groups and higher numbers of hydrogen sulfide-producing bacteria than fecal samples from indigenous Africans. Additionally, the fecal concentrations of secondary bile acids such as LCA and DCA, were higher in African Americans, whereas the concentrations of SCFAs such as acetate, butyrate, and propionate, were higher in indigenous Africans.[@B56]

In fact, previous reports on dietary fat consumption and CRC risk have shown that secondary bile acids are increased and SCFAs are decreased in patients with CRC.[@B57][@B58] Similarly, consumption of diets rich in beef also affects the composition of the intestinal microbiota. The abundance of *B. fragilis* was significantly higher in individuals consuming a diet rich in beef than in those consuming a vegetarian diet.[@B31] The enterotoxigenic form of *B. fragilis*, enterotoxigenic *B. fragilis* (ETBF), is associated with acute diarrheal disease, IBD (as discussed above), and CRC due to production of the *B. fragilis* toxin.[@B59] *B. fragilis* toxin alters the structure and function of colonic epithelial cells, and cleaves the tumor suppressor protein E-cadherin, which is critical for the formation and maintenance of adherent junctions in areas of epithelial cell-cell contact. The toxin increases the permeability of the epithelial barrier and enhances Wnt/β-catenin signaling, resulting in an increased colonic carcinoma cell population.[@B60]

Importantly, colonization by ETBF, but not non-toxigenic *B. fragilis*, promotes colonic colitis and carcinogenesis in CRC model *Min^APC716\ +/-^* mice.[@B61] This finding indicates that in *Min^APC716\ +/-^* mice, ETBF specifically activates STAT3, a key regulator of CRC development, by increasing IL-17 production by Th17 cells in the colonic tissue. Blocking IL-17 or IL-23R can significantly reduce tumor formation *in vivo*.[@B61] ETBF tends to be more abundant in patients with CRC than in healthy individuals.[@B62] Genotoxins also have a considerable effect on the composition of microbial communities and can promote tumorigenesis. The adherent-invasive *E. coli* strain NC101 induces DNA double-strand breaks by utilizing several of the enzymes involved in the production of colibactin, which are encoded on the polyketide synthase (*pks*) genotoxic island.[@B63] Although monocolonization of azoxymethanetreated germ-free *Il10^-/-^* mice by *E. coli* NC101 promoted tumor formation and intestinal inflammation, monocolonization of these mice by a *pks*-deleted mutant showed significantly reduced tumor multiplicity and invasion.[@B64] However, colonization of azoxymethane-treated wild-type germ-free mice by *E. coli* NC101 does not result in tumor development, suggesting that bacteria-driven inflammation is required for carcinogenesis mediated by this bacterium.[@B64] It is noteworthy that *pks^+^ E. coli* tend to be more abundant in patients with IBD or CRC than in patents without IBD and CRC.[@B64]

High consumption of alcohol also increases the risk of CRC.[@B65] A higher incidence of CRC was observed in heavy drinkers than in non-drinkers, and the microbial composition in the gut of these two groups was different.[@B66] Mutlu et al. showed that intestinal dysbiosis is observed in persons with alcoholism. In particular, the abundance of Bacteroidetes is lower and the abundance of Proteobacteria is higher in people with alcoholism than in healthy controls.[@B67] Interestingly, the abundance of gram-positive *Erysipelotrichaceae*, which are considered to be pro-inflammatory (as described above), was higher in chronic alcohol-fed mice than in control mice.[@B68] This observation also holds true in CRC patients.[@B69] Expression of REG3γ, an antimicrobial peptide that targets gram-positive bacteria, was downregulated in alcohol-fed mice. This result suggests that alcohol consumption leads to an overgrowth of *Erysipelotrichaceae* due to lower REG3γ expression. Collectively, these findings support the notion that excess alcohol consumption leads to the development of CRC through dysbiosis, although the underlying mechanism remains unclear.

The aging process also plays a key role in CRC pathogenesis, and aging has been shown to affect the composition of the human microbiota. Studies of the relationship between age and microbiota composition have demonstrated that both the total number of bacteria and bacterial diversity decrease with age. In fact, a lower abundance of Firmicutes and a higher abundance of Bacteroidetes were observed in older populations.[@B70][@B71] There is also evidence that older age is associated with decreased butyrate production and reduced numbers of *F. prausnitzii* and *Roseburia intestinalis*,[@B72] antiinflammatory bacteria with protective roles against CRC.[@B73] Thus, the aging process may affect gut homeostasis, thereby increasing the risk of CRC development.

Bacteria of the genus *Fusobacterium* are oral commensal organisms that maintain epithelial barrier function by producing butyrate.[@B74] However, these bacteria have pathogenic potential in the gut. For example, an invasive strain of *Fusobacterium nucleatum* has been shown to promote the onset of colonic tumorigenesis by mediating E-cadherin/β-catenin signaling *via* an adhesion protein called FadA.[@B75] *F. nucleatum* has also been shown to be highly prevalent in the intestinal tissue and stool of patients with CRC.[@B76] These findings suggest that although *F. nucleatum* is a beneficial commensal bacterium, its abnormal accumulation may increase the risk of CRC.

All of these findings suggest that changes in the structure, distribution, and metabolism of the colonic microbiota, which can be triggered by diverse factors, may contribute to the development and progression of CRC. A better understanding of the mechanisms that influence homeostasis of the gut microbiota will pave the way for novel and effective approaches to prevent and treat CRC ([Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

3. Celiac Disease
-----------------

Celiac disease, a chronic immune-mediated inflammatory disease of the small intestine, is an autoimmune disorder triggered by the consumption of dietary gluten.[@B77] Studies suggest that alterations in the gut microbiota composition may contribute to the development and/or progression of celiac disease.[@B78] Changes in the intestinal metabolic profile, including alterations in SCFA production, have also been reported in patients with celiac disease.[@B79] It has been reported that *Klebsiella oxytoca*, *Staphylococcus epidermidis*, and *Staphylococcus pasteuri* are more abundant in duodenal biopsy specimens from patients with active celiac disease than in specimens from healthy individuals. In contrast, *Streptococcus anginosus* and *Streptococcus mutans* are less abundant in patients with celiac disease than in healthy individuals, regardless of inflammation status.[@B80]

Notably, some of the changes in the gut microbiota of patients with celiac disease cannot be restored after long-term treatment with a gluten-free diet,[@B81] indicating that dysbiosis might be related to a celiac disease-associated genotype. Parmer et al. showed that a mutation in the fucosyltransferase 2 (*FUT2*) gene, which controls the expression of ABH blood group antigens in mucus and other body secretions,[@B82] is associated with the pathogenesis of celiac disease,[@B83] although the mechanism that underlies this phenomenon has not yet been fully elucidated. Additionally, FUT2 can influence the structure of mucosa-associated bacteria,[@B84] and *FUT2* mutations have been shown to lead to reduced bacterial diversity and richness, including a lower abundance of *Bifidobacterium* spp., in the human gut.[@B85] Decreased abundance of *Bifidobacterium* spp. is associated with an increased risk for autoimmune diseases,[@B86] and *Bifidobacterium* spp. are known to protect against *Candida albicans* colonization. *Fut2*-null mice display greater susceptibility to *C. albicans* colonization than wild-type mice,[@B87] and *C. albicans* infection can trigger the onset of celiac disease.[@B88] Therefore, perturbations of the microbiota due to *FUT2* mutation result in lower resistance to colonization by pathobionts, thus contributing to the pathogenesis of celiac disease.

Antibiotic exposure is also a recognized risk factor for the development of celiac disease.[@B89] Perinatal antibiotic treatment (vancomycin) of gluten-sensitive NOD/DQ8 mice worsened gluten-induced pathology[@B90] and led to an overall decrease in fecal microbial diversity. Although the abundance of Proteobacteria, including *Escherichia* and *Helicobacter* spp., was enhanced, that of *Bacteroides* and *Parabacteroides* spp. was significantly decreased.[@B90] This finding provides additional evidence for the role of the gut microbial community in the development of celiac disease and confirms the relationship between antibiotic use and an increased risk of celiac disease.

Previous epidemiological analyses showed that breastfeeding of infants exerts protective effects against the development of celiac disease. This effect is believed to be mediated by the establishment of specific gut microbiota.[@B91][@B92] Meta-analysis demonstrated that the risk of later celiac disease was significantly reduced in infants who were breastfed when gluten-containing foods were introduced compared to infants who were not breastfed during this period.[@B92][@B93] Breastfeeding is known to promote gut colonization by *Bifidobacterium* spp. However, a recent study has showed that *Bifidobacterium* spp. are less abundant in the breast milk of mothers with celiac disease, suggesting that infants raised by mothers with celiac disease may have decreased numbers of *Bifidobacterium* spp.[@B94] This result suggests that breastfeeding may protect infants against the development of celiac disease and that this protective effect is modulated by the microbiota.

It is unclear whether alterations of the microbiota and its components are a cause or a consequence of the development of celiac disease. The fact that both newly diagnosed celiac disease patients as well as those that have been treated with a gluten-free diet have imbalanced microbiotas indicates that the gut microbiota may play a primary role in the pathogenesis of celiac disease. Further research using animal models is needed to elucidate the mechanism by which the microbiota shapes host immune response against gluten ([Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

4. Irritable Bowel Syndrome
---------------------------

Irritable Bowel Syndrome (IBS) is a functional bowel disorder that commonly causes abdominal pain, diarrhea, cramping, gas, and constipation.[@B95] A growing number of studies have demonstrated that gut dysbiosis is involved in IBS pathogenesis; specifically gut motility dysfunction, intestinal permeability, and visceral pain responses.[@B96][@B97] Patients with IBS have greater numbers of *Ruminococcaceae* and *Clostridium cluster* XIVa, and lesser numbers of Bacteroides than healthy individuals do.[@B98] It is unclear whether intestinal dysbiosis is the cause of IBS or merely a consequence. The results of animal-based studies support the latter hypothesis. For instance, colonization of germ-free rats with dysbiotic fecal microbiota (e.g., increased *Bifidobacteria* and decreased *Enterobacteriaceae* and sulfate-reducing bacteria) isolated from IBS patients was sufficient to cause increased abdominal contractions, a typical symptom of patients with IBS. This observation confirms that the gut dysbiosis present in patients with IBS contributes to disease pathogenesis.[@B99]

Patients with IBS also display defects in luminal metabolic function, which is likely caused by dysbiosis. The degree of breath methane production is markedly enhanced in patients with IBS and is correlated with the incidence of constipation. [@B100] Methane has a negative effect on various aspects of GI motility, including gut transit and contraction. Consistent with the observation of increased methane production, *Methanobrevibacter smithii*, a predominant methanogen in the human gut,[@B101] was shown to be more abundant in stool samples from patients with constipation-predominant IBS.[@B100] Thus, methanogenic bacteria appear to play a role in the pathogenesis of IBS; however, the factors that promote the bloom of methanogenic bacteria in patients with IBS are not yet known. These findings indicate that microbial imbalance leads to gut dysfunction and contributes to IBS symptoms. Moreover, several meta-analyses have shown that the pathogenesis of IBS is influenced by multiple factors, all of which can result in gut dysbiosis.[@B96] For example, intestinal infections with pathogenic bacteria such as *Salmonella*, *Campylobacter*, and *Shigella*, are known to increase the risk of developing IBS.[@B102] Although enteric infections may directly influence GI motility, infection-induced dysbiosis may also contribute to post-infectious IBS symptoms.[@B103][@B104] Moreover, epidemiologic studies have shown that the incidence of IBS symptoms is significantly increased in patients who, as children, were treated with antibiotics, particularly macrolides and tetracycline.[@B105][@B106]

In summary, the effects of physical and psychological stressors and dietary factors such as fat consumption, on IBS have been extensively studied.[@B96] However, the precise mechanisms by which these factors influence the gut microbial profile and lead to the development and/or progression of IBS are still unknown. Thus, more research is required to advance our current understanding of the relationship between the intestinal microbiota and gut dysfunction in IBS ([Table 1](#T1){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

PERSPECTIVE
===========

Mounting evidence suggests that the initiation and development of GI diseases are governed by multiple factors. As described above, current studies indicate that the phenotype associated with commensal bacteria can shift from symbiotic to pathogenic in response to several risk factors. These phenotypic alterations impact the host immune system and the other microorganisms, thereby leading to the development and/or progression of various GI diseases.[@B107] Based on this evidence, therapeutic approaches that aim to correct perturbations of the intestinal bacterial structure and its metabolic function will likely be most effective for the treatment of GI diseases. For example, it has been reported that a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) reduces GI symptoms in IBS patients by altering the microbial composition and colonic luminal environment, including the pH and SCFA level.[@B108][@B109]

Additionally, healthy fecal microbiota transfer (FMT) appears to be effective for the treatment of IBD.[@B110] In a clinical study, all tested patients with IBD showed resolution of *C. difficile* symptoms post-FMT.[@B111] In addition, FMT increased bacterial diversity and richness to levels similar to those of healthy donors.[@B112] Similarly, consumption of beneficial microorganisms, called probiotics, has shown great promise as a potential therapeutic approach for the treatment and prevention of CRC.[@B113] Although more clinical trials are clearly needed, the potential role of probiotics in CRC has been evaluated. Administration of *Lactobacillus johnsonii* modulated immune responses and decreased the risk of pathogen colonization in CRC patients.[@B114] Other studies have demonstrated that the administration of *Lactobacillus casei* prevented the growth of colorectal tumors in CRC patients for at least 4 years after treatment.[@B115]

These trials were limited by the small number of patients included and the short experimental period. Therefore, in the future, larger studies are required to explore the full therapeutic potential of gut microbiota modulation in the treatment of GI diseases.
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  Risk factor                                      Microbial change                                                         Possible mechanisms                                                                      Ref.
  ------------------------------------------------ ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ----------------------------------------
  IBD                                                                                                                                                                                                                
   Genetics (Nlrp6 deficient)                      *Prevotellaceae* ↑, TM7 ↑                                                IL-18↓, CCL5↑, and innate and adaptive immune cell recruitment                           [@B14], [@B15], [@B16]
   Genetics (IL-10, IL-2 deficient)                *Escherichia coli or Enterococcus faecalis*(monocolonization)            IL-12, IFN-γ ↑                                                                           [@B23]
   Genetics (HLA-B27)                              *Bacteroides fragilis* (*monocolonization*)                              Unknown                                                                                  [@B24]
   Diet (high fat derived from milk)               Firmicutes ↓, *Bilophila wadsworthia* ↑                                  Immune system (Th1) disruption                                                           [@B26], [@B27]
   Diet (high protein)                             *Desulfovibrio spp .* ↑, *Desulfuromonas spp .* ↑                        Genotoxic ↑, DNA damage ↑, inflammation ↑                                                [@B28], [@B29]
   Diet (high fat, high beef)                      *Erysipelotrichaceae* ↑, *Bacteroides fragilis* ↑                        Unknown                                                                                  [@B30], [@B31]
   Smoking                                         *Anaerostipes* ↓                                                         Butyrate ↓                                                                               [@B35]
   Antibiotics (ciprofloxacin, metronidazole)      *Dorea*↓, *Butyricicoccus* ↓, *Coriobacteriaceae* ↓                      Organic acid ↓ (e.g., formic acid, butyrate)                                             [@B40], [@B41]
   Antibiotics                                     *Clostridium scindens* ↓, *Clostridium difficile* ↑                      DCA ↓                                                                                    [@B47]
   Unknown                                         *Faecalibacterium prausnitzii* ↓                                         Anti-inflammatory effect ↓                                                               [@B50], [@B51]
   Unknown                                         *pks+ Escherichia coli*↑                                                 Colibactin ↑, DNA damage ↑                                                               [@B64]
  CRC                                                                                                                                                                                                                
   Diet (high fat, low fiber)                      Butyrate-producing bacteria ↓, hydrogen sulfide-producing bacteria ↑     SCFAs ↓ (e.g., acetate, butyrate, propionate), secondary bile acids ↑ (e.g., LCA, DCA)   [@B56], [@B57], [@B58]
   Diet (high beef)                                *Bacteroides fragilis* (ETBF) ↑                                          Wnt/β-catenin signaling ↑ IL-17-driven STAT3 ↑                                           [@B31], [@B59], [@B60], [@B61], [@B62]
   Alcohol                                         *Erysipelotrichaceae* ↑                                                  Unknown                                                                                  [@B68], [@B69]
   Aging                                           *Faecalibacterium prausnitzii* ↓, *Roseburia intestinalis*↓              Butyrate ↓, anti-inflammatory property ↓                                                 [@B72], [@B73]
   Unknown                                         *pks+ Escherichia coli* ↑                                                Colibactin ↑, DNA damage ↑                                                               [@B64]
   Unknown                                         *Fusobacterium nucleatum*↑                                               E-cadherin/β-catenin signaling ↑                                                         [@B75], [@B76]
  Celiac disease                                                                                                                                                                                                     
   Genetics (*FUT2* mutation)                      *Bifidobacterium spp.* ↓, *Candida albicans* ↑                           Unknown                                                                                  [@B85], [@B87], [@B88]
   Antibiotic (Vancomycin)                         *Bacteroides*↓, *Parabacteroides* ↓, *Escherichia* ↑, *Helicobacter* ↑   Unknown                                                                                  [@B90]
   Breastfeeding (by mother with celiac disease)   *Bifidobacterium*spp. ↓                                                  Unknown                                                                                  [@B92], [@B93], [@B94]
  IBS                                                                                                                                                                                                                
   Infection                                       *Salmonella* ↑, *Campylobacter*↑, *Shigella* ↑                           Unknown                                                                                  [@B102]
   Unknown                                         *Methanobrevibacter smithii* ↑                                           Methane-driven gut dysfunction                                                           [@B100], [@B101]

CCL5, Chemokine ligand 5; NIrp, NOD like receptor protein; IL, interleukin; IFN, interIferon; protein; DCA, deoxycholic acid; *pks*, polyketide synthases; CRC, colorectal cancer; SCFA, short chain fatty acids; LCA, lithocholic acid; ETBF, *enterotoxigenic Bacteroides fragilis*; STAT3, Signal transducer and activator of transcription 3; FUT2, fucosyltransferase 2; spp, species.
